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Diabetic kidney disease is the leading cause of end-stage renal disease in developed and developing countries.
Microalbuminuria is the gold standard for detection and prediction of diabetic kidney disease and cardiovascular
risk disease in clinical practice. However, microalbuminuria has several limitations, such as lower sensitive, larger
variability. It is urgent to explore higher sensitivity and specificity for earlier detection of diabetic kidney disease and
more accurate prediction of the progression to end stage renal disease. We reviewed some new and important
urinary biomarkers, such as: transferrin, immunoglobulin G, immunoglobulin M, Cystanic C, podocytes, type IV
collagen, 8-oxo-7, 8-dihydro-2'-deoxyguanosine, ceruloplasmin, monocyte chemoattractant protein-1 and so on. We
need good quality, long-term, large longitudinal trials to validate published biomarkers and find new biomarkers,
considering biomarkers reviewed here are from small cross-sectional studies.
Keywords: Diabetic kidney disease, Biomarker, UrineDiabetes mellitus (DM) is a chronic disease that affects
366 million people worldwide (6.4% of the adult popula-
tion) and is expected to rise to 552 million by 2030 [1].
Diabetic kidney disease (DKD) is one of the most serious
microvascular complications, which significantly impacts
morbidity, mortality and quality of life. DKD occurs in ap-
proximately one-third of all people with diabetes and is
the leading cause of renal failure in developed and devel-
oping countries. The first sign of DKD is considered to be
microalbuminuria in clinical practice, while microalbumi-
nuria has several limitations such as lower sensitive and
larger variability. Therefore, earlier, more sensitive and
specific biomarkers with greater predictability are needed.
The aim of this review is to summarize new urinary bio-
markers for glomerular injury associated with DKD.Transferrin
Transferrin, a plasma protein, is very similar to albumin in
weight. It is more readily filtered through glomerular bar-
rier than albumin for being less anionic. Urinary transferrin
is considered to be a more sensitive marker of glomerular
damage in diabetic patients based on theory analysis and* Correspondence: wt770716@163.com
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reproduction in any medium, provided the orexperimental results. Urinary transferrin excretion shows a
good linear relationship with urinary albumin excretion in
diabetic patients, and increased urinary transferrin excre-
tion predicts the development of microalbuminuria in type
2 diabetic patients with normoalbuminuria [2]. A systemic
review, including 13 studies, indicated that urinary trans-
ferrin excretion was a good marker for predicting onset of
nephropathy [3]. However, urinary transferrin excretion is
not specific for DKD because its elevation can be found in
primary glomerulonephritis [4].Immunoglobulin G
Immunoglobulin G (IgG) is a protein synthesized and
secreted by plasma cells. It has a molecular weight of 150
kDa, which is larger than albumin. Urinary IgG excretion is
higher in diabetic patients compared to healthy controls,
and its excretion in diabetic patients with normoalbumi-
nuria predicts the development of microalbuminuria [5].
Urinary IgG excretion correlates with the progression of
glomerular diffuse lesions. One IgG isoform (IgG4) has been
used more specifically as a marker of glomerular charge
selectivity impairment. Only IgG4 excretion is elevated
in patients with microalbuminuria, while the excretion of
both IgG and IgG4 are increased in patients with macroal-
buminuria compared with normoalbuminuric patients [6].
Recently, one study found that urinary concentration ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cantly higher than in healthy control, whereas further
elevation of IgG2, IgG4, and IgA was more pronounced
in patients with microalbuminuria. Fractional excretion
of IgG2 was the highest among all immunogloubins,
which indicated that elevation of those particular immu-
nogloubin subtypes was a contribution of novel mechan-
isms in early DKD, different from charge and size barrier
impairment [7]. One systemic review, including 13 stud-
ies, indicated urinay IgG was a good marker for predict-
ing onset of nephropathy [3].
Immunoglobulin M
Immunoglobulin M (IgM), secreted by plasma cells, is
the largest antibody in the human. Due to its large mo-
lecular radius, the appearance of IgM in urine indicates
that a large, nonselective pore exists in the glomerular
capillary wall. One study showed that urine excretion of
IgM was significantly higher in type 2 DM compared to
type 1 DM, and patients with type 2 DM with nephro-
sclerosis had significantly higher urine excretion of IgM
compared to the age-matched healthy subjects [8]. An-
other study found renal survival of type 2 diabetic
patients was inversely associated with urine IgM excre-
tion, which indicated that higher urinary IgM excretion
was a better predictor of decline in kidney function than
albuminuria in type 2 DM. However, urinary IgM excre-
tion has not been regarded as an early marker of DKD,
since its excretion in urine is associated with severe in-
jury of the glomerular capillary wall, while it is also a
promising marker which may predict the eventual need
for renal replacement therapy [9].
Cystatin C
Cystatin C, a cysteine protease inhibitor, is a novel bio-
marker of renal damage. Serum Cystatin c is a good
marker for assessing renal injuries, while urinary cystatin
c was considered as a useful marker for the detection of
DKD. One study from Zucker diabetic fatty (ZDF) rats
indicated that urinary cystatin C was increased in ZDF
rats where renal damage was not observed by histo-
pathological assessment, and its levels in urine increased
with the progression of renal damage, demonstrating the
usefulness of early detection and accurate assessment of
DKD [10]. Another study from type 2 diabetic patients
found that urinary cystatin C increased with increasing
degree of albuminuria and reached higher levels in
macroalbuminuric patients. Urinary cystatin C levels
were identified as an independent factor associated with
estimated glomerular filtration rate (eGFR) < 60ml/min/
1.73m2 in patients with normoalbuminuria, which indi-
cated urinary cystatin C levels could be a useful marker
for renal dysfunction in type 2 diabetic patients with
normoalbuminuria [11].Podocytes
Podocytes are key structural elements of the glomerular
filtration barrier. It is accepted that podocytes’ injuries
play an essential role in the progression of DKD [12].
Monitoring urine podocytes and podocyte-specific pro-
teins can reveal potentially interesting urinary markers
for the early diagnosis of DKD [13]. Podocytes in urine
can be found in diabetic patients with micro- and
macroalbuminuria [14]. Another study indicated that
nephrinuria was found to be present in 100% of diabetic
patients with micro- and macroalbuminuria, as well as
54% of patients with normoalbuminuria; what’s more,
nephrinuria also correlated positively with albuminuria,
which suggested that nephrinuria might be a biomarker
of early DKD [15]. Urinary podocalyxin was higher in
53.8% patients at the normoalbuminuric stage, 64.7% at
the microalbuminuric stage and 66.7% at the macroalbu-
minuric stage, which indicated that urinary podocalyxin
might be a useful biomarker for detecting early podocyte
injury in diabetic patients [16]. Another study found that
urinary mRNA profiles of synaptopodin, podocalyxin, α-
actin-4, and podocin were increased with the progres-
sion of DKD, which suggested that quantification of
podocyte-associated molecules in urine will be a useful
biomarker of DKD [17].
Type IV Collagen
Type IV collagen is the main constituent of both glom-
erular and tubular basement membranes as well as
mesangial matrix. Urinary type IV collagen was signifi-
cantly increased in both normoalbuminuric and microal-
buminuric patients of type 2 DM compared with healthy
controls, and urinary type IV collagen significantly corre-
lated with the amount of albuminuria [18]. Another
study found that urinary type IV collagen was more sen-
sitive than albuminuria to detect renal damage in type 2
diabetic patients. A follow-up study showed that 25% of
normoalbuminuric patients with increased urinary type
IV collagen excretion developed microalbuminuria, while
patients who stayed normoalbuminuria had a significant
decrease in urinary type IV collagen excretion, which
suggested that urinary type IV collagen is a marker to
detect the progression of DKD [19,20].
8-oxo-7, 8-dihydro-2'-deoxyguanosine
It is well known that increased oxidative stress in
diabetes contributes to the progression of diabetes and
its complications. 8-oxo-7, 8-dihydro-2'-deoxyguanosine
(8-oxodG), a marker of intracellular oxidative stress,
can be assessed non-invasively in urine. Patients with
higher excretion of 8-oxodG in urine compared with
those patients with moderate or lower excretion of
8-oxodG showed significant progression of diabetic
nephropathy, which indicates that 8-oxodG in urine is
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diabetic nephropathy [21,22].
Ceruloplasmin
Ceruloplasmin (molecular weight =151 kD) is the major
copper-carrying protein in blood and more negatively
charged than albumin, which makes it difficult to be fil-
tered by the glomerulus. Urinary ceruloplasmin was found
in normoalbuminuric diabetic patients, and its increase in
urine had a predictive value for development of microal-
buminuria in normoalbuminuric diabetic patients [23,24].
The ceruloplasmin/creatinine ratio is higher in DKD com-
pared with non-diabetic patients, and its ratio has a sensi-
tivity of 90-91%, specificity of 61–66% in diagnosing DKD
[25]. All these data suggest that urinary ceruloplasmin is a
promising marker of DKD, while further studies are
needed to characterize its value compared to albuminuria,
especially in type 1 diabetics, since all the studies have
been done in type 2 diabetics.
Monocyte chemoattractant protein-1(MCP-1)
Chemokines have been implicated in the pathogenesis of
DKD, therefore, measurement of cytokine in urine might
help to diagnosis DKD. Urinary MCP-1/creatinine in
patients with macroalbuminuria was significantly higher
than patients with normoalbuminuria and microalbumi-
nuria, and urinary MCP-1 correlated with the rate of eGFR
decline [26]. Another study found that urinary MCP-1 was
significantly higher in patients presenting doubling of serum
creatinine or death, and its levels were positively associated
with the risk of doubling of serum creatinine or death after
Cox regression; what’s more, urinary MCP-1 remained as
significant independent predictors of doubling of serum cre-
atinine or death [27]. All these data suggested that urinary
MCP-1 might be a prognostic marker for progression of dia-
betic nephropathy, while more studies are needed to investi-
gate whether urinary MCP-1 has a role in the setting of
normoalbuminuria and microalbuminuria in DKD.
Neutrophil gelatinase-associated lipocalin
Neutrophil gelatinase-associated lipocalin (NGAL) has
been evaluated in several studies of diabetic subjects.
In one study, urine NGAL was 5–10-fold higher in
normo- or microalbuminuric patients compared with
healthy controls. Another study from short-term type 2
DM patients indicated urinary NGAL showed a negative
correlation with eGFR, which suggested urinary NGAL
might be a promising early marker for monitoring renal
impairment in short-term T2DM patients [28]. Study
from type 1 DM indicated that urine NGAL levels corre-
lated with albumin/creatinine, and patients with higher
albuminuria had higher urine NGAL levels, which sug-
gested that elevated urinary NGAL values might indicate
kidney damage [29].Identification of urinary markers by proteomic
approaches
Proteomics is a method aimed at discovering and identify-
ing the complete set of proteins present in a given bio-
logical sample at a given time. Using a variant of two
dimensional gel electrophoresis, they found urine samples
from type 2 DM patients with microalbuminuria showed
four main proteins accompanying with albumin: alpha-2
glycoprotein, alpha-1 acid glycoprotein, alpha-1 microglo-
bulin and IgG [30]. Otu found a 12-peak proteomic signa-
ture in the baseline urine of type 2 DM patients who
subsequently developed DKD [31]. The reported accur-
acy (71% sensitivity and 76% specificity) is encouraging
in view of a future diagnostic assay. Zürbig used capillary
electrophoresis-coupled mass spectrometry to profile the
low-molecular weight proteome in urine samples from a
longitudinal cohort of type 1 and 2 diabetic patients. They
found collagen fragments were prominent biomarkers be-
fore onset of macroalbuminuria, and there is a decrease in
collagen fragments before albumin excretion starts to in-
crease [32]. Urinary proteomics enables noninvasive as-
sessment of DN risk at an early stage, while more studies
are needed to investigate the role of urinary proteomics in
diabetic kidney disease.
Novel biomarkers
Recently, a study from uni-nephrectomized diabetic rats
indicated urinary osteopontin, heart-type fatty acid binding
protein appeared before the classical biomarkers of diabetic
nephropathy, such as albuminuria and urinary protein ex-
cretion [33]. Study of males with Type 2 diabetes indicated
human zinc-α (2) -glycoprotein might be a novel urinary
biomarker for non-albuminuric diabetic nephropathy [34].
Another study suggested urinary mRNA levels of α-smooth
muscle actin, fibronectin and matrix metalloproteinase-9
might be novel biomarkers of diabetic kidney disease [35].
McKittrick reported that urinary matrix metalloproteinase
activity might be a sensitive, noninvasive, and clinically use-
ful biomarker for predicting vascular remodeling in diabetic
renal and vascular complications [36]. The above men-
tioned results are from small patient population and from
animal experiments, which lead to limited use for clinical
practice. We need larger perspective studies to confirm the
utility of these biomarkers in diabetic kidney disease
Conclusion and future directions
The current gold standard for detection and prediction
of DKD is microalbuminuria; however, it has several lim-
itations, such as lower sensitive and larger variability. It
is urgent to explore higher sensitivity and specificity for
earlier detection of DKD and more accurate prediction
of the progression to end stage renal disease. Despite
numbers of new biomarkers described, most studies are
limited by either their small sample size or their cross-
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center trials enlisting both Type 1 and Type II diabetic
patients with and without nephropathy for at least two
decades to indentify there role in clinical practice.
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